Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease

INTRODUCTION: There is a substantial unmet need for effective therapies to treat patients with refractory dry eye disease (DED). The goal of this open-label pilot study was to investigate the efficacy and safety of repository corticotropin injection (RCI; Acthar® Gel; Mallinckrodt Pharmaceuticals) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyos, Melissa, Toyos, Rolando, Jodoin, Barbara, Bunch, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114278/
https://www.ncbi.nlm.nih.gov/pubmed/35460497
http://dx.doi.org/10.1007/s40123-022-00501-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114278/
https://www.ncbi.nlm.nih.gov/pubmed/35460497
http://dx.doi.org/10.1007/s40123-022-00501-2

Ejemplares similares